Generative AI can increase revenue for information companies and reduce research costs while enhancing product quality, but it may pose higher risks for less-specialized customers, Bloomberg intelligence analysis shows.

Clinical trials are a significant part of the drug development cycle. However, the process has remained unchanged in recent decades. Integrating AI should allow developers to adopt a more data-driven approach, improving efficiencies without reducing success rates.

EURUSD Five consecutive days of negative closing, EURUSD fell further today to 1.0543, the lowest since October 2023 as USD index strength continued, DXY traded higher today at 106.72, the highest in a year. Macroeconomics from EZ remained weak, while the US inflation increased by 2.6 in October which means that the Fed is unlikely […]

FTSE 100 up 0.1, FTSE 250 flat Nov 15 Reuters The main UK stock indexes were subdued on Friday, with losses in AstraZeneca and GSK weighing on the bluechip FTSE 100, while data showed Britain39;s economy contracted unexpectedly in September. Shares of drugmakers AstraZeneca dropped 2.4 and GSK dipped 3.2, tracking losses in U.S. and European vaccine […]

LONDON, Nov 15 Reuters The pound headed for its biggest weekly loss since January on Friday, under pressure from weak UK economic data and a surging dollar that is getting a lift from investors39; conviction that Donald Trump39;s policies will drive up U.S. growth and inflation. Britain39;s economy contracted unexpectedly in September and growth slowed to a […]